Cargando…
Cardiovascular safety trials of incretin‐based drugs: What do they mean?
Incretin‐based dipeptidyl peptidase‐4 inhibitors and glucagon‐like peptide‐1 receptor agonists are newer choices of antidiabetic medications that are now most widely used worldwide. Preclinical study results suggest that the two drugs potentially exert benefits to prevent onsets and/or progressions...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415478/ https://www.ncbi.nlm.nih.gov/pubmed/27612317 http://dx.doi.org/10.1111/jdi.12576 |